EGFR and lung adenocarcinoma: For example, Epidermal growth factor receptor mutation, which is the most common mutation in lung cancer patients in Taiwan (approximately 40% of patients with lung adenocarcinoma) [23,24,25,26], can be treated effectively with target therapy, while the use of chemotherapy might not bring comparably promising survival benefit [23,26,27,28,29,30,31,32].